The renaissance of barrier methods

Abstract

In 1987, the threat of litigation led to the withdrawal of intrauterine devices (IUDs) from the American market where depot medroxyprogesterone acetate (DMPA) had already been banned. There were fears of repercussions that would have led to the limiting of contraceptive choice in Britain. HIV was also an emerging issue and a revival of interest in barrier contraception led to an emphasis on male condoms, with strengthening of manufacturing standards, promotion in the media, improved accessibility and emphasis of their value for dual protection. Twenty-five years later, links still need to be sought within reproductive health services, especially at the interface between the management of contraception and opportunities for HIV prevention.